Dynamics Special Purpose Corp.
DYNS
NASDAQ Capital Market7.51
USD
-0.49
- -
Dynamics Special Purpose Corp.
DYNS
(NASDAQ Capital Market)
Recent
price
7.51
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Dynamics Special Purpose Corp. (Nasdaq: DYNS) operates as a blank check company, or special purpose acquisition company, with no significant ongoing operations and focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination, primarily targeting opportunities in healthcare and life sciences sectors including synthetic biology, novel drug discovery, and enabling platforms for prevention, diagnosis, and treatment; it does not manufacture or sell products but holds cash in trust from its initial public offering for deployment in such transactions. Founded in 2021 and headquartered at 2875 El Camino Real, Redwood City, California, the company went public in May 2021 raising approximately $230 million and serves investors seeking exposure to high-growth life sciences targets without direct operational assets or revenue generation. In its most significant development, Dynamics Special Purpose Corp. completed a definitive business combination with Senti Biosciences, Inc. in June 2022 through a reverse recapitalization, providing Senti Bio with gross proceeds of about $140 million after redemptions from trust cash, PIPE financing, and strategic investment, after which Senti Bio commenced trading under the ticker SNTI on Nasdaq while Dynamics' structure supported the going-public transaction; post-merger, DYNS shares continue to trade with low volume and short interest as of mid-2022 data, amid indications of potential delisting risks and no further disclosed acquisitions, partnerships, or strategic shifts in 2024-2025.
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Synthetic Biology Platform Senti Bio Rides On Omid Farokhzad's SPAC For NASDAQ Debut
Cathie Wood Makes Adjustments to Portfolio in August
U.S. IPO Weekly Recap And Week Ahead